What are the major opportunities in the Pulmonary Drugs market? What are the strategies for the Pulmonary Drugs market?

For detailed insights on the major opportunities and strategies in the Pulmonary Drugs market, Read More

How does the Pulmonary Drugs market relate to the overall economy and other similar markets?

For detailed insights on Pulmonary Drugs's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Pulmonary Drugs market growth? SWOT analysis of the Pulmonary Drugs market.

For detailed insights on the key dynamics influencing the Pulmonary Drugs market growth and SWOT analysis of the Pulmonary Drugs industry, Read More

Pulmonary Drugs Market Global Report 2026 Market Report Infographic Image

Published : April 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Pulmonary Drugs Market Report 2026

Name: Pulmonary Drugs Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes), By Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies) – Market Size, Trends, Strategies, and Forecast to 2035

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Pulmonary Drugs Market Overview

• Pulmonary Drugs market size has reached to $56.98 billion in 2025

• Expected to grow to $74.14 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%

• Growth Driver: Rising Prevalence Of Respiratory Diseases Driving Demand For Pulmonary Drugs Due To Increasing Infectious Disease Burden

• Market Trend: Verona Pharma’s Ohtuvayre™ Approval Marks First Novel COPD Therapy in Over Two Decades

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pulmonary Drugs Market?

Pulmonary drugs refer to medications that target the respiratory system to improve lung function, reduce inflammation, and manage airway disorders. They are used for treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses.

The main drug class of pulmonary drugs is inhaled corticosteroids, long-acting beta-2 agonists, antihistamines, vasodilators, short acting beta-2 agonists, and others. Inhaled corticosteroids are anti-inflammatory medications delivered directly to the lungs via inhalers to manage chronic respiratory conditions like asthma and COPD by reducing airway inflammation and preventing flare-ups. The various indications include asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others and they are distributed through several channels such as retail pharmacies, online pharmacies, and hospital pharmacies.

Pulmonary Drugs Market Global Report 2026 Market Report bar graph

What Is The Pulmonary Drugs Market Size and Share 2026?

The pulmonary drugs market size has grown strongly in recent years. It will grow from $56.98 billion in 2025 to $60.07 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increasing asthma prevalence, rising COPD incidence, urban air pollution growth, expansion of inhalation drug delivery, improved diagnosis of respiratory diseases.

What Is The Pulmonary Drugs Market Growth Forecast?

The pulmonary drugs market size is expected to see strong growth in the next few years. It will grow to $74.14 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to aging population growth, expansion of biologic pulmonary drugs, precision respiratory medicine adoption, increasing smoking-related disorders, improved access to inhaled therapies. Major trends in the forecast period include rising adoption of targeted respiratory therapies, growth of combination inhalation treatments, increasing focus on long-term disease control, expansion of biologic-based pulmonary drugs, shift toward personalized respiratory care.

Book your 30 minutes free consultation with our research experts

Global Pulmonary Drugs Market Segmentation

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Is The Driver Of The Pulmonary Drugs Market?

The increasing prevalence of respiratory diseases is expected to propel the growth of the pulmonary drugs market going forward. Respiratory disorders refer to medical conditions that affect the lungs and airways, impairing normal breathing and oxygen exchange. Respiratory disorders are increasing due to the growing prevalence of smoking, leading to lung damage and chronic diseases. Pulmonary drugs play a crucial role in managing respiratory disorders by improving lung function, reducing inflammation, and relieving airway obstruction for better breathing. For instance, in May 2025, according to the Centers for Disease Control and Prevention, a US-based government agency reported that in 2023, the age-adjusted COPD prevalence among adults 18+ was 3.8%, with higher rates in women (4.1%) than men (3.4%). COPD prevalence rose sharply with age, from 0.4% in adults 18–24 to 10.5% in those 75 and older. Therefore, the rising respiratory diseases are driving the growth of the pulmonary drugs industry.

Key Players In The Global Pulmonary Drugs Market

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Global Pulmonary Drugs Market Trends and Insights

Major companies operating in the pulmonary drugs market are focusing on therapeutic innovation, such as dual PDE3 and PDE4 inhibition via inhaled delivery, to combine bronchodilator and non-steroidal anti-inflammatory effects in a single molecule for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Dual PDE3 and PDE4 inhibition enables simultaneous airway relaxation and reduction of lung inflammation, addressing persistent COPD symptoms more effectively than traditional therapies and simplifying administration without requiring complex inhalation techniques. For instance, in June 2024, Verona Pharma plc, a UK-based biopharmaceutical company, received U.S. FDA approval for Ohtuvayre (ensifentrine), the first inhaled therapy with this dual-mechanism profile in more than 20 years. Delivered via standard jet nebulizer, Ohtuvayre provides bronchodilator and anti-inflammatory benefits in a single dose, showing clinical efficacy both as monotherapy and in combination with other maintenance treatments in the Phase 3 ENHANCE trials, and is expected to be available through specialty pharmacies in the U.S. by the third quarter of 2024.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Pulmonary Drugs Market?

In September 2024, Roivant Sciences Ltd., a US-based biotechnology company, acquired medicine for pulmonary hypertension manufactured by Bayer AG for an undisclosed amount. With this acquisition, Roivant aims to expand its respiratory portfolio and advance innovative treatments for pulmonary hypertension, enhancing patient outcomes and addressing unmet medical needs. Bayer AG is a Germany-based company that manufactures pulmonary drugs, including treatments for respiratory conditions such as pulmonary hypertension.

Regional Insights

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pulmonary Drugs Market?

The pulmonary drugs market consists of the sales of inhalers, nebulizers, bronchodilators, anti-inflammatory agents, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pulmonary Drugs Market Report 2026?

The pulmonary drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Pulmonary Drugs Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$60.07 billion
Revenue Forecast In 2035	$74.14 billion
Growth Rate	CAGR of 5.4% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Drug Class, Indication, Distribution Channel
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Pulmonary Drugs Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Pulmonary Drugs Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Pulmonary Drugs Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Pulmonary Drugs Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Rising Adoption Of Targeted Respiratory Therapies

4.2.2 Growth Of Combination Inhalation Treatments

4.2.3 Increasing Focus On Long-Term Disease Control

4.2.4 Expansion Of Biologic-Based Pulmonary Drugs

4.2.5 Shift Toward Personalized Respiratory Care

5. Pulmonary Drugs Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Pulmonology Clinics

5.3 Specialty Respiratory Centers

5.4 Homecare Providers

5.5 Ambulatory Care Centers

6. Pulmonary Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Pulmonary Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Pulmonary Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Pulmonary Drugs Market Size, Comparisons And Growth Rate Analysis

7.3. Global Pulmonary Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Pulmonary Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Pulmonary Drugs Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Pulmonary Drugs Market Segmentation

9.1. Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

9.2. Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

9.3. Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

9.4. Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

9.5. Global Pulmonary Drugs Market, Sub-Segmentation Of Long-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

9.6. Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

9.7. Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

9.8. Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

9.9. Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

10. Pulmonary Drugs Market Regional And Country Analysis

10.1. Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Pulmonary Drugs Market

11.1. Asia-Pacific Pulmonary Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Pulmonary Drugs Market

12.1. China Pulmonary Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Pulmonary Drugs Market

13.1. India Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Pulmonary Drugs Market

14.1. Japan Pulmonary Drugs Market Overview

14.2. Japan Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Pulmonary Drugs Market

15.1. Australia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Pulmonary Drugs Market

16.1. Indonesia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Pulmonary Drugs Market

17.1. South Korea Pulmonary Drugs Market Overview

17.2. South Korea Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Pulmonary Drugs Market

18.1. Taiwan Pulmonary Drugs Market Overview

18.2. Taiwan Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Pulmonary Drugs Market

19.1. South East Asia Pulmonary Drugs Market Overview

19.2. South East Asia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Pulmonary Drugs Market

20.1. Western Europe Pulmonary Drugs Market Overview

20.2. Western Europe Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Pulmonary Drugs Market

21.1. UK Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Pulmonary Drugs Market

22.1. Germany Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Pulmonary Drugs Market

23.1. France Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Pulmonary Drugs Market

24.1. Italy Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Pulmonary Drugs Market

25.1. Spain Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Pulmonary Drugs Market

26.1. Eastern Europe Pulmonary Drugs Market Overview

26.2. Eastern Europe Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Pulmonary Drugs Market

27.1. Russia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Pulmonary Drugs Market

28.1. North America Pulmonary Drugs Market Overview

28.2. North America Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Pulmonary Drugs Market

29.1. USA Pulmonary Drugs Market Overview

29.2. USA Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Pulmonary Drugs Market

30.1. Canada Pulmonary Drugs Market Overview

30.2. Canada Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Pulmonary Drugs Market

31.1. South America Pulmonary Drugs Market Overview

31.2. South America Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Pulmonary Drugs Market

32.1. Brazil Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Pulmonary Drugs Market

33.1. Middle East Pulmonary Drugs Market Overview

33.2. Middle East Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Pulmonary Drugs Market

34.1. Africa Pulmonary Drugs Market Overview

34.2. Africa Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Pulmonary Drugs Market Regulatory and Investment Landscape

36. Pulmonary Drugs Market Competitive Landscape And Company Profiles

36.1. Pulmonary Drugs Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Pulmonary Drugs Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Pulmonary Drugs Market Company Profiles

36.3.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Chiesi Farmaceutici S.p.A. Overview, Products and Services, Strategy and Financial Analysis

37. Pulmonary Drugs Market Other Major And Innovative Companies

Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

38. Global Pulmonary Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Pulmonary Drugs Market

40. Pulmonary Drugs Market High Potential Countries, Segments and Strategies

40.1 Pulmonary Drugs Market In 2030 - Countries Offering Most New Opportunities

40.2 Pulmonary Drugs Market In 2030 - Segments Offering Most New Opportunities

40.3 Pulmonary Drugs Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Pulmonary Drugs Market, Overview Of Key Products - Product Examples

Table 2: Global Pulmonary Drugs Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Pulmonary Drugs Market, Supply Chain Analysis

Table 4: Global Pulmonary Drugs Market, Major Raw Material Providers

Table 5: Global Pulmonary Drugs Market, Major Resource Providers

Table 6: Global Pulmonary Drugs Market, Major Manufacturers (Suppliers)

Table 7: Global Pulmonary Drugs Market, Major Distributors And Channel Partners

Table 8: Global Pulmonary Drugs Market, Key Technologies & Future Trends

Table 9: Global Pulmonary Drugs Market, Major Trends

Table 10: Global Pulmonary Drugs Market, Major End Users

Table 11: Global Pulmonary Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Pulmonary Drugs Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Pulmonary Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Pulmonary Drugs Market - TAM, US$ Billion, 2025

Table 15: Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Pulmonary Drugs Market, Sub-Segmentation Of Long-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: China, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: China, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: India, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: India, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Japan, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Japan, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Australia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Australia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Indonesia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: Indonesia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South Korea, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: South Korea, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Taiwan, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: Taiwan, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: South East Asia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: South East Asia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Western Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: Western Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: UK, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: UK, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Germany, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: Germany, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: France, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: France, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Italy, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Italy, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Spain, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Spain, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Eastern Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Eastern Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: Russia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: Russia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: North America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: North America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: USA, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: USA, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Canada, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: Canada, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: South America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: South America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Brazil, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Brazil, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Middle East, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Middle East, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Africa, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 97: Africa, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 98: Global Pulmonary Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 99: Global Pulmonary Drugs Market - Company Scoring Matrix

Table 100: AstraZeneca plc Financial Performance

Table 101: GlaxoSmithKline plc Financial Performance

Table 102: Novartis AG Financial Performance

Table 103: Boehringer Ingelheim International GmbH Financial Performance

Table 104: Chiesi Farmaceutici S.p.A. Financial Performance

Table 105: Global Pulmonary Drugs Market, Competitive Benchmarking (In USD Billions)

Table 106: Global Pulmonary Drugs Market, Competitive Dashboard

Table 107: Global Pulmonary Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 108: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030

Table 109: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030

Table 110: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

Figure 1: Global Pulmonary Drugs Market, Overview Of Key Products - Product Examples

Figure 2: Global Pulmonary Drugs Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Pulmonary Drugs Market, Supply Chain Analysis

Figure 4: Global Pulmonary Drugs Market, Major Raw Material Providers

Figure 5: Global Pulmonary Drugs Market, Major Resource Providers

Figure 6: Global Pulmonary Drugs Market, Major Manufacturers (Suppliers)

Figure 7: Global Pulmonary Drugs Market, Major Distributors And Channel Partners

Figure 8: Global Pulmonary Drugs Market, Key Technologies & Future Trends

Figure 9: Global Pulmonary Drugs Market, Major Trends

Figure 10: Global Pulmonary Drugs Market, Major End Users

Figure 11: Global Pulmonary Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Pulmonary Drugs Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Pulmonary Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Pulmonary Drugs Market - TAM, US$ Billion, 2025

Figure 15: Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Pulmonary Drugs Market, Sub-Segmentation Of Long-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: China, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: China, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: India, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: India, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Japan, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Japan, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Australia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Australia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Indonesia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: Indonesia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South Korea, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: South Korea, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Taiwan, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: Taiwan, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: South East Asia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: South East Asia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Western Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: Western Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: UK, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: UK, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Germany, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: Germany, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: France, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: France, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Italy, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Italy, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Spain, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Spain, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Eastern Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Eastern Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: Russia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: Russia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: North America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: North America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: USA, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: USA, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Canada, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: Canada, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: South America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: South America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Brazil, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Brazil, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Middle East, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Middle East, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Africa, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 97: Africa, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 98: Global Pulmonary Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 99: Global Pulmonary Drugs Market - Company Scoring Matrix

Figure 100: AstraZeneca plc Financial Performance

Figure 101: GlaxoSmithKline plc Financial Performance

Figure 102: Novartis AG Financial Performance

Figure 103: Boehringer Ingelheim International GmbH Financial Performance

Figure 104: Chiesi Farmaceutici S.p.A. Financial Performance

Figure 105: Global Pulmonary Drugs Market, Competitive Benchmarking (In USD Billions)

Figure 106: Global Pulmonary Drugs Market, Competitive Dashboard

Figure 107: Global Pulmonary Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 108: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030

Figure 109: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030

Figure 110: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Anti-Asthmatic And COPD Drugs Market 2021 - By Drug Class (Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs), By End User (Asthma Patients, COPD Patients), By Distribution Channel (Gener...

Pulmonary Drug Delivery Devices Market Report 2026 - Global Outlook – By Product Type (Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers), By Application (Asthma, Cystic Fibrosis, Chronic Obstructive Pulmonary Disea...

Lung Cancer Drugs Market Report 2026 - Global Outlook – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung cance...

Inhalable Drugs Market Report 2026 - Global Outlook – By Product (Aerosol, Dry Powder Formulation, Spray), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Other Distribution Channels), By Application (Respir...

Asthma Drugs Market Report 2026 - Global Outlook – By Type Of Asthma (Allergic, Non-Allergic), By Asthma Trigger Type (Adult-Onset Asthma, Child-Onset Asthma, Cough-Induced Asthma, Exercise-Induced Asthma, Occupational A...

Pulmonary Arterial Hypertension Market Report 2026 - Global Outlook – By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Route Of Administ...

Inhaled Antibiotics Market Report 2026 - Global Outlook – By Product Type (Aerosol Or Metered Dose Inhaler, Dry Powder Formulation, Spray, Other Types), By Application (Pneumonia, Bronchitis, Other Applications), By End-...

Frequently Asked Questions

How big is the Pulmonary Drugs Market?

The Pulmonary Drugs market was valued at $56.98 billion in 2025, increased to $60.07 billion in 2026, and is projected to reach $74.14 billion by 2030.

What is the Pulmonary Drugs market growth?

The global Pulmonary Drugs market is expected to grow at a CAGR of 5.4% from 2026 to 2035 to reach $74.14 billion by 2035.

Who are the key players in Pulmonary Drugs market?

Some Key Players in the Pulmonary Drugs market Include, AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc. .

What is the anticipated growth trend for the Pulmonary Drugs market?

Major trend in this market includes: Verona Pharma’s Ohtuvayre™ Approval Marks First Novel COPD Therapy in Over Two Decades . For further insights on this market. request a sample here

Which region has the most growth potential in the Pulmonary Drugs market?

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.